On our article regarding the liquidation of Eden Bioscience Corp, we estimated liquidation distribution to stockholders at $1.60/share. It is now clear that we underestimated the costs associated with professional fees associated with the company’s dissolution. We also underestimated the expenses expected to be incurred until the time of liquidation. We now estimate the liquidation value at $1.30/share, which indicates there is currently no discrepancy between value and price. We are exiting our position at the current market price of $1.28/share.